blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3679941

EP3679941 - SAFE DESMOPRESSIN ADMINISTRATION [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  16.06.2023
Database last updated on 16.07.2024
FormerThe patent has been granted
Status updated on  08.07.2022
FormerGrant of patent is intended
Status updated on  16.11.2021
FormerRequest for examination was made
Status updated on  22.10.2021
FormerGrant of patent is intended
Status updated on  09.06.2021
FormerRequest for examination was made
Status updated on  08.01.2021
FormerThe application has been published
Status updated on  12.06.2020
Most recent event   Tooltip26.01.2024Lapse of the patent in a contracting state
New state(s): MC		published on 28.02.2024  [2024/09]
Applicant(s)For all designated states
Acerus Pharmaceuticals USA, LLC
500 Office Center Drive
Suite 400
Fort Washington, PA 19034 / US
[2022/45]
Former [2022/44]For all designated states
Acerus Pharmaceuticals USA, LLC
c/o The Corporation Trust Company
Corpoation Trust Center
1209 Orange Street
Wilmington, DE 19081 / US
Former [2022/24]For all designated states
Serenity Pharmaceuticals LLC
7025 Langer Drive, Suite 205
Mississauga, ON L5N 0E8 / CA
Former [2020/29]For all designated states
Serenity Pharmaceuticals LLC
105 Hawk Court
Milford, PA 18337 / US
Inventor(s)01 / FEIN, Seymour
476 Canoe Hill Road
New Canaan, CT Connecticut CT 06840 / US
 [2020/29]
Representative(s)Simmons & Simmons
City Point
One Ropemaker Street
London EC2Y 9SS / GB
[2022/32]
Former [2020/29]EIP
EIP Europe LLP
Fairfax House
15 Fulwood Place
London WC1V 6HU / GB
Application number, filing date19202083.215.06.2010
[2020/29]
Priority number, dateUS200926895409P18.06.2009         Original published format: US 26895409 P
[2020/29]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3679941
Date:15.07.2020
Language:EN
[2020/29]
Type: B1 Patent specification 
No.:EP3679941
Date:10.08.2022
Language:EN
[2022/32]
Search report(s)(Supplementary) European search report - dispatched on:EP27.05.2020
ClassificationIPC:A61K38/095, A61M11/06, A61M15/08, A61P5/10, A61P7/12, A61P13/02
[2020/29]
CPC:
A61K38/095 (EP,KR,US); A61K9/0043 (EP,KR,US); A61K9/10 (KR);
A61K9/1075 (EP); A61K9/12 (KR); A61M11/008 (EP,KR,US);
A61M11/06 (EP,KR,US); A61M15/08 (EP,KR,US); A61P13/00 (EP);
A61P13/02 (EP); A61P25/00 (EP); A61P5/10 (EP);
A61P7/12 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2021/06]
Former [2020/29]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  SM,  TR 
TitleGerman:SICHERE VERABREICHUNG VON DESMOPRESSIN[2020/29]
English:SAFE DESMOPRESSIN ADMINISTRATION[2020/29]
French:ADMINISTRATION SÛRE DE DESMOPRESSINE[2020/29]
Examination procedure06.01.2021Examination requested  [2021/06]
06.01.2021Date on which the examining division has become responsible
10.06.2021Communication of intention to grant the patent
20.10.2021Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
17.11.2021Communication of intention to grant the patent
04.05.2022Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
01.07.2022Fee for grant paid
01.07.2022Fee for publishing/printing paid
01.07.2022Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP10790053.2  / EP2442821
EP17168865.8  / EP3278809
Divisional application(s)EP22189129.4  / EP4104848
Opposition(s)11.05.2023No opposition filed within time limit [2023/29]
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
01.07.2022Request for further processing filed
01.07.2022Full payment received (date of receipt of payment)
Request granted
12.07.2022Decision despatched
Fees paidRenewal fee
10.02.2020Renewal fee patent year 03
10.02.2020Renewal fee patent year 04
10.02.2020Renewal fee patent year 05
10.02.2020Renewal fee patent year 06
10.02.2020Renewal fee patent year 07
10.02.2020Renewal fee patent year 08
10.02.2020Renewal fee patent year 09
10.02.2020Renewal fee patent year 10
29.06.2020Renewal fee patent year 11
28.06.2021Renewal fee patent year 12
27.06.2022Renewal fee patent year 13
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL10.08.2022
CZ10.08.2022
EE10.08.2022
FI10.08.2022
HR10.08.2022
LT10.08.2022
LV10.08.2022
MC10.08.2022
RO10.08.2022
SI10.08.2022
SK10.08.2022
SM10.08.2022
GR11.11.2022
IS10.12.2022
[2024/09]
Former [2023/37]AL10.08.2022
CZ10.08.2022
EE10.08.2022
FI10.08.2022
HR10.08.2022
LT10.08.2022
LV10.08.2022
RO10.08.2022
SI10.08.2022
SK10.08.2022
SM10.08.2022
GR11.11.2022
IS10.12.2022
Former [2023/29]AL10.08.2022
CZ10.08.2022
EE10.08.2022
FI10.08.2022
HR10.08.2022
LT10.08.2022
LV10.08.2022
RO10.08.2022
SK10.08.2022
SM10.08.2022
GR11.11.2022
IS10.12.2022
Former [2023/23]CZ10.08.2022
EE10.08.2022
FI10.08.2022
HR10.08.2022
LT10.08.2022
LV10.08.2022
RO10.08.2022
SK10.08.2022
SM10.08.2022
GR11.11.2022
IS10.12.2022
Former [2023/22]CZ10.08.2022
FI10.08.2022
HR10.08.2022
LT10.08.2022
LV10.08.2022
RO10.08.2022
SM10.08.2022
GR11.11.2022
IS10.12.2022
Former [2023/20]FI10.08.2022
HR10.08.2022
LT10.08.2022
LV10.08.2022
SM10.08.2022
GR11.11.2022
IS10.12.2022
Former [2023/12]FI10.08.2022
HR10.08.2022
LT10.08.2022
LV10.08.2022
GR11.11.2022
IS10.12.2022
Former [2023/10]FI10.08.2022
HR10.08.2022
LT10.08.2022
LV10.08.2022
GR11.11.2022
Former [2023/09]FI10.08.2022
LT10.08.2022
LV10.08.2022
Former [2023/08]FI10.08.2022
LT10.08.2022
Documents cited:Search[A]US5731303  (HSIEH DEAN [US]) [A] 1-15* examples 2,3 *;
 [A]WO2009003199  (CYDEX PHARMACEUTICALS INC [US], et al) [A] 1-15 * page 50, paragraph 2; examples 24,33,35 *;
 [A]US2009005432  (FEIN SEYMOUR H [US]) [A] 1-15 * paragraphs [0006] , [0108] - [0111] *;
 [A]US2009035260  (VERONESI PAOLO ALBERTO [IT], et al) [A] 1-15 * paragraphs [0062] - [0068] *;
 [E]WO2010075266  (SERENITY PHARMACEUTICALS CORP [US], et al) [E] 1-15 * paragraphs [0038] , [0042]; example - *;
 [E]WO2010075327  (SERENITY PHARMACEUTICALS CORP [US], et al) [E] 1-15 * paragraphs [0037] , [0040] , [0041]; example - *
by applicantUS3980631
 US4148787
 US4548922
 US4746508
 US4860738
 US4944429
 US5023252
 US5112804
 US5122383
 US5154122
 US5212199
 US5227169
 US5314694
 US5719122
 US5731303
 US6321942
 US6446839
 US2003232078
 US6705493
 US6708846
 US6772915
 US7112561
 US7182226
 US7244703
 US7335186
 US7405203
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.